Literature DB >> 16228809

Healing of transmetatarsal amputation in the diabetic patient: is angiography predictive?

Boulos Toursarkissian1, Ryan T Hagino, Khurram Khan, John Schoolfield, Paula K Shireman, Lawrence Harkless.   

Abstract

Transmetatarsal amputation (TMA) is a durable reconstruction in the diabetic patient with limited forefoot gangrene. However, predicting TMA healing remains difficult. Our goals were to (1) determine the success rate of TMA and (2) identify factors predictive of TMA healing, in particular arterial foot anatomy. A retrospective review of all diabetic patients undergoing TMA was done. Blood supply to the foot was classified as mostly anterior (anterior tibial and/or dorsalis pedis artery), mostly posterior (posterior tibial or plantar arteries), or equally distributed (both systems patent or peroneal runoff). Foot vessels were assigned runoff scores from 0 to 3 according to Society for Vascular Surgery/International Society for Cardiovascular Surgery (SVS/ISCVS) criteria. Forty-four TMAs in 29 men and 12 women were reviewed. Revascularization was done in 35 cases. In nine cases (20%), no bypass was deemed necessary (n = 7) or feasible (n = 2). Blood flow to the foot was deemed mostly anterior in 16 cases, mostly posterior in 17 cases, and equally distributed in 11. The TMA was left open in 19 cases and closed with staples or sutures in the rest. Limb salvage was achieved in 30 cases (68%) at a median follow-up of 48 weeks. Three of the four patients on dialysis required leg amputation (75%) vs. 11 of the 40 (27%) nondialysis patients (p = 0.05). When the TMA was left open, leg amputation was more likely (58%) than when closed primarily (12%) (p < 0.01). No angiographic factors were predictive of limb salvage. The need for revascularization was not associated with limb loss, although both patients with no feasible bypass option required below-knee amputation. TMA healing can be expected in a majority of diabetic patients after adequate revascularization but cannot be predicted by angiographic findings. Efforts should be made to achieve primary wound closure.

Entities:  

Mesh:

Year:  2005        PMID: 16228809     DOI: 10.1007/s10016-005-7969-z

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  7 in total

1.  Functional and Patient-reported Outcomes following Transmetatarsal Amputation in High-risk Limb Salvage Patients.

Authors:  Romina Deldar; Gina Cach; Adaah A Sayyed; Brian N Truong; Emily Kim; Jayson N Atves; John S Steinberg; Karen K Evans; Christopher E Attinger
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-05-25

Review 2.  The care of transmetatarsal amputation in diabetic foot gangrene.

Authors:  Michele Ammendola; Rosario Sacco; Lucia Butrico; Giuseppe Sammarco; Stefano de Franciscis; Raffaele Serra
Journal:  Int Wound J       Date:  2016-10-03       Impact factor: 3.315

3.  [Minor amputations for diabetic foot syndrome].

Authors:  G Rümenapf; W Lang; S Morbach
Journal:  Orthopade       Date:  2009-12       Impact factor: 1.087

4.  Review of Transmetatarsal Amputations in the Management of Peripheral Arterial Disease in an Asian Population.

Authors:  Ming Ngan Aloysius Tan; Zhiwen Joseph Lo; Soon Hong Lee; Rui Ming Teo; Wei Leong Glenn Tan; Sadhana Chandrasekar
Journal:  Ann Vasc Dis       Date:  2018-06-25

5.  Transmetatarsal Amputation Results in Higher Frequency of Revision Surgery and Higher Ambulation Rates Than Below-Knee Amputation.

Authors:  Angel Ordaz; Conner Trimm; Jason Pedowitz; Ian M Foran
Journal:  Foot Ankle Orthop       Date:  2022-07-21

Review 6.  Transmetatarsal Amputation Outcomes When Utilized to Address Foot Gangrene and Infection: A Retrospective Chart Review.

Authors:  Richard C Harris; Wei Fang
Journal:  J Foot Ankle Surg       Date:  2020-08-14       Impact factor: 1.286

Review 7.  Lower extremity reamputation in people with diabetes: a systematic review and meta-analysis.

Authors:  Rongqi Liu; Brian J Petersen; Gary M Rothenberg; David G Armstrong
Journal:  BMJ Open Diabetes Res Care       Date:  2021-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.